ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
6,045.26
0.38%
US Tech 100
21,346.40
0.00%
Dow Jones
42,967.62
0.24%
Brent Oil
73.015
4.45%
Bitcoin
105,058.04
-0.82%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Estrella Immunopharma Inc (ESLA) Quote

Estrella Immunopharma Inc

Estrella Immunopharma Inc (ESLA)

NASDAQ
1.01
0.00
(0.00%)
Closed June 13 4:00PM
15 min delayed - Upgrade to Realtime
0.00
0.00
(0.00%)
After Hours: -
15 min delayed - Upgrade to Realtime

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.01
Bid
0.98
Ask
0.99
Volume
-
0.00 Day's Range 0.00
0.63 52 Week Range 3.23
Market Cap
36.527M
Previous Close
1.01
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
219,626
Shares Outstanding
36,165,589
Dividend Yield
-
PE Ratio
-8.25
Earnings Per Share (EPS)
-0.12
Revenue
-
Net Profit
-4.43M

About Estrella Immunopharma Inc

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed o... Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE). Show more

Sector
Blank Checks
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
2021
Estrella Immunopharma Inc is listed in the Blank Checks sector of the NASDAQ with ticker ESLA. The last closing price for Estrella Immunopharma was $1.01. Over the last year, Estrella Immunopharma shares have traded in a share price range of $ 0.63 to $ 3.23.

Estrella Immunopharma currently has 36,165,589 shares outstanding. The market capitalization of Estrella Immunopharma is $36.53 million. Estrella Immunopharma has a price to earnings ratio (PE ratio) of -8.25.

Ask ADVFN Intelligence (AI)

ESLA Latest News

More News
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.09-8.181818181821.11.130.9365427201.02569914CS
40.01111.180.785370790.84573181CS
120.08799.532588656330.92211.250.73012196260.86576991CS
26-0.1064-9.53063418131.11641.780.73011353670.95356042CS
520.088.602150537630.933.230.631252211.20113287CS
156-4.2-80.61420345495.215.620.63946911.31301397CS
260-4.2-80.61420345495.215.620.63946911.31301397CS

ESLA - Frequently Asked Questions (FAQ)

What is the current Estrella Immunopharma share price?
The current share price of Estrella Immunopharma is $ 1.01
How many Estrella Immunopharma shares are in issue?
Estrella Immunopharma has 36,165,589 shares in issue
What is the market cap of Estrella Immunopharma?
The market capitalisation of Estrella Immunopharma is USD 36.53M
What is the 1 year trading range for Estrella Immunopharma share price?
Estrella Immunopharma has traded in the range of $ 0.63 to $ 3.23 during the past year
What is the PE ratio of Estrella Immunopharma?
The price to earnings ratio of Estrella Immunopharma is -8.25
What is the reporting currency for Estrella Immunopharma?
Estrella Immunopharma reports financial results in USD
What is the latest annual profit for Estrella Immunopharma?
The latest annual profit of Estrella Immunopharma is USD -4.43M
What is the registered address of Estrella Immunopharma?
The registered address for Estrella Immunopharma is 108 W. 13TH STREET, SUITE 100, WILMINGTON, DELAWARE, 19801
Which industry sector does Estrella Immunopharma operate in?
Estrella Immunopharma operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0

ESLA Discussion

View Posts
glenn1919 glenn1919 1 week ago
ESLA.....................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
81vette 81vette 4 months ago
Scanners will find this,mine did,it will only take 1 with 20k+ followers to promote this and with the current no manipulation(freely trading) it could jump up quickly
👍️0
81vette 81vette 4 months ago
new bio pharma,trading freely,72%inside!10m float,45Xs buying ave.(serious loading,on 1st trial news)
👍️0
81vette 81vette 4 months ago
Golden cross https://stockcharts.com/h-sc/ui?s=esla
👍️0
81vette 81vette 4 months ago
Buys 2x the sells,nearly no dark trades https://ih.advfn.com/stock-market/NASDAQ/estrella-immunopharma-ESLA/trades
👍️0
81vette 81vette 4 months ago
Nice chart,moving freely is rare!
In 10k@1.55
👍️0
tedpeele tedpeele 4 months ago
ESLA $16 12 month price target, news today - moving forward
👍️0
tedpeele tedpeele 4 months ago
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
4:46 PM ET 2/19/25 | BusinessWire

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
EMERYVILLE, Calif.--(BUSINESS WIRE)--February 19, 2025--

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS(R) T-cell therapies to treat cancer and autoimmune diseases, today announced that D. Boral Capital LLC ("D. Boral Capital"), a leading investment bank, has initiated coverage on the Company, assigning a Buy rating to Estrella and established a 12-month price target of $16.00.

Valuation Highlights
-- D. Boral Capital's analysis focuses on the development of EB103 in B-cell
Non-Hodgkin's Lymphoma, emphasizing Estrella's ARTEMIS(R) T-cell
engineering platform that utilizes cellular mechanisms which closely
resemble those of endogenous T-cell receptors, producing a more natural
and regulated immune response.

-- The derived 12-month price target of $16.00 underscores market confidence
in Estrella's potential to capture significant market share in
immuno-oncology.

-- The models incorporate a 30% probability of success along with a 30%
discount rate, reflecting the early stage of Estrella's clinical
development.
👍️0
Monksdream Monksdream 6 months ago
ESLA, under $2
👍️0
glenn1919 glenn1919 6 months ago
ESLA.......................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 months ago
ESLA..........................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 months ago
ESLA...................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 months ago
ESLA......................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 months ago
ESLA....................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 months ago
ESLA........................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 8 months ago
ESLA.........................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 11 months ago
ESLA.....................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0

Your Recent History

NASDAQ
ESLA
Estrella Immunopharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads